Report Date: 2026-11-15 | Coverage: Elderly care institutions, home & community services, rehabilitation medicine, and payer structure | Industry View: Divergent
Core Judgment: The volume driven by population aging is the most certain demand base over the next three decades, but who captures the profit is determined by payers' pricing mechanisms—government-priced segments (the LTC insurance 36-item catalog, medical insurance per-day-bed payment, inclusive pricing caps) lock service margins into single digits, while market-priced segments (C-end home-use devices, high-end CCRC) and equipment/assistive-device segments are where real profit accrues. National rollout of LTC insurance (basic full coverage by end-2028) and disability consumption subsidies constitute the payment-system inflection point, but their realization slope is back-loaded and the magnitude is below market consensus: under this report's base case, public payers' share of the disability care payment pool is roughly 31% in 2030 (vs. ~23% in 2025), not a nonlinear leap. Segments within the industry vary sharply in temperature—picking the right segment matters more than picking the industry.
(This industry is analyzed under the generic value-chain framework: a services industry with no futures pricing or supply-demand balance sheet; "balance" is expressed via occupancy rates, benefit coverage rates, and labor gaps.)
This report covers China's elderly care services and silver economy, divided into four layers along the value chain:
Key point on competitive boundaries: elderly care institutions and home services compete for the same disability-care payment (LTC insurance benefits + subsidies + out-of-pocket), while rehabilitation medicine competes for medical insurance's post-acute inpatient budget—the two payment logics differ and must not be conflated; silver consumption (tourism/products) rides on pensions and household wealth, with weak correlation to the care line's cycle.
Structural vs. cyclical: Demand-side growth is ultra-long-term structural—a certainty determined by birth cohorts, weakly correlated with economic cycles. Cyclical disturbances only affect supply-side funding (local fiscal payment pace) and high-end consumption (wealth effects). H1 2025 senior tourism revenue rose +26.2% YoY (tax invoice data, as cited), showing the counter-cyclical resilience of silver consumption.
Urban employees' average monthly pension is ~RMB 3,985 per person (2025 estimate), vs. only ~RMB 246 for urban-rural residents (of which the national minimum basic pension is RMB 143/month, to be raised to RMB 163 in 2026)—a ~16x payment-capacity gap means: commercializable care demand is highly concentrated among urban-employee retirees (~150 million beneficiaries) and high-net-worth families, while rural and lower-tier markets depend entirely on fiscal support (346.6 million rural destitute elderly are fiscally supported). The scissors gap between "demand population" and "paying demand" is the biggest trap in industry revenue modeling.
Physical volume bridge (institutional beds): Registered institution beds 5.077 million (2024) → ~5.81 million needed by 2030 (estimate: 370 million elderly × 14.5% disability rate × 6.5% institutional penetration ÷ 60% occupancy), a net increase of ~735,000 beds; institutionalized elderly 2.307 million → ~3.487 million (penetration 5.1%→6.5%). Drivers: +8.65 million disabled population, penetration pushed by the triple payment of LTC insurance institutional care benefits + subsidies + centralized care for financially strapped disabled elderly.
Payment fund bridge (disability care payment pool): ~RMB 198.2 billion in 2025 → ~RMB 332.7 billion base case by 2030 (net increase ~RMB 134.4 billion); composition in I4. Within it, LTC insurance beneficiaries 1.9291 million (2025) → base 4 million (2030), fund expenditure RMB 18.644 billion → ~RMB 38.7 billion.
Note: The 2028 milestone is the "national basic full coverage" point (enrollment coverage ≠ benefit coverage; see D1); the 2030 range of 3.2–4.8 million corresponds to bear-bull scenarios. Current benefit rate is only 0.62% of enrollees—the ramp-up slope is the largest source of expectation gaps in this industry.
Silver economy total: ~RMB 7 trillion (2023/2024) → ~RMB 30 trillion by 2035 (NDRC expert estimate, implied CAGR ~14%); bottom-up population × consumption cross-check gives ~RMB 13.4 trillion for 2030, vs. top-down interpolated RMB 15.5 trillion—a ~13% deviation, cross-validation passed (lower bound conservative). Sub-segment growth ranking: senior tourism (+26%) > age-friendly retrofitting (subsidy-driven volume) > elderly products > institutional care (low-base penetration but payment-constrained).
As of end-2025, elderly care institutions and facilities totaled 395,000, with combined beds of 7.679 million (Ministry of Civil Affairs statistical communiqué)—a net decrease of ~480,000 beds (-5.9%) from the 2021 peak of 8.159 million; the 14th Five-Year Plan target of 9 million beds was not met. This is not an under-supplied industry expanding capacity, but supply clearing: average occupancy of registered institutions is only 45.4% (2024: 2.307 million ÷ 5.077 million beds), halved from 77% in 2010 over fifteen years; industry break-even is 60%–80% (occupancy basis), with the national average far below. People's Daily reported in October 2025 an industry wave of "departures/closures," with vacancy rates above 60% in some regions.
Structurally: nursing-type beds rose to 67.5% of total (2025, MCA)—low-end self-care homes consolidated while nursing-type beds expanded counter-cyclically—supply is "raising quality, controlling quantity," aligning with rigid disability demand.
Elderly care worker gap of ~5.5 million (China Aging Development Foundation 2024 report; another estimate puts the demand gap above 10 million with only 500,000 certified); annual attrition among new care workers is 40%–50%, and over 30% earn no more than RMB 4,000/month. Elderly care institution employees: 722,000 (end-2025, +12.2%). On rehabilitation: ~1.19 rehab therapists per 10,000 population, with a 2030 target of 1.6 (implied gap ~58,000); against the international standard of 50 therapists per 100,000 population, the gap runs into the hundreds of thousands. The low-wage–high-attrition–low-quality cycle is a systemic constraint on service supply, and the first bottleneck on whether payment expansion can convert into services (rather than wage inflation).
Typical private institution at full occupancy: ~RMB 5,700/month per bed—labor RMB 2,500 (44%) + rent RMB 1,300 (23%) + food RMB 850 (15%) + depreciation RMB 400 (7%) + administration RMB 350 (6%) + utilities RMB 300 (5%) (Guangzhou and other first-tier field surveys; labor share of revenue at some mature institutions has risen to 52%). Heavy-asset anchor: insurance-capital CCRC planned investment ~RMB 1.7 million/bed (2018 CIRC figure, 29 projects RMB 67.82 billion ÷ 40,000+ beds); new CCRC takes 4–6 years from land acquisition to opening, 5–8 years from opening to break-even, 8–10 years payback under leasing models, and only ~4% of institutions are stably profitable (Taikang Foundation report).
Against the revenue side: mainstream private institution monthly fees are RMB 4,000–8,000 (People's Daily), while average monthly income of the elderly in 2021 was ~RMB 2,669—the inversion between "incentive pricing" and payment capacity is the root cause of supply contraction, and the reason LTC insurance as a payer carries such high expectations.
Rehabilitation hospitals: 810 (2021, NHC yearbook; only 268 in 2010, CAGR ~10.6%); ~0.4 rehab nursing beds per 1,000 population (~563,000 beds). In October 2026 the State Council approved the Implementation Plan for the Medical Rehabilitation & Nursing Capacity Expansion and Enhancement Project: "15th Five-Year" targets of 0.48 rehab nursing beds per 1,000 population (implied net increase ~113,000 beds), 1.6 rehab therapists per 10,000 population, and at least one public rehabilitation hospital in prefecture-level cities with large rehab needs—this is national-level order visibility for rehab equipment and private rehab chains, but as a 2030 planning target, realization depends on central investment and local fiscal capacity.
(No futures or inventory in this industry; "balance and price" is organized by payer × unit economics. This chapter, alongside I5, is a headline section of this report.)
Disability care payment pool 2025: ~RMB 198.2 billion—out-of-pocket RMB 152.26 billion (76.8%) + LTC insurance funds RMB 18.644 billion (9.4%, +42.2% YoY) + fiscal care spending RMB 27.32 billion (13.8%); separately listed elderly welfare allowances of RMB 48.94 billion (old-age allowances etc., not care-service payments). Commercial insurance is nearly blank: disability income-loss insurance premiums in 2023 were only RMB 1.416 billion (0.04% of health insurance).
Real-data calibration of the two new payers (key expectation gaps):
2030 base payment pool: ~RMB 332.7 billion (public share 30.9%; bear case RMB 289.0 billion/25.6%, bull case RMB 381.4 billion/35.8%). Out-of-pocket remains the largest payer, with share halving to ~69%—payment structure improvement is gradual; there is no scenario of "public payers taking over overnight."
Regulated-segment profit formula = volume growth with locked prices: locked unit prices + lagged price adjustments + rigid labor cost inflation mean providers can only grow profit via benefit-recipient volume and labor efficiency, not via price.
Institutional per-bed: Second-tier inclusive private monthly fee RMB 4,000–8,000 vs. full-occupancy cost ~RMB 5,700—at 60% occupancy, revenue ~RMB 3,600/bed covers only variable costs (cash-flow break-even), full-cost balance requires 80%+ occupancy; the national average occupancy of 45.4% means most institutions have not even reached cash-flow balance (illustrative estimate: an RMB 6,000/month-fee institution at 60% occupancy loses ~RMB 300–500/bed/month, net margin ~-8% to -10%). First-tier high-end (Taikang basis): nursing wing ~RMB 17,500/month per bed, heavy-asset investment ~RMB 1.7 million/bed, single-community cash balance in 6–8 years, profit in 8–10 years.
Home single site (LTC insurance-designated nursing station, Shanghai basis): Average ~323 benefit-eligible elderly per site; severe tier (levels 5–6) ticket size ~RMB 1,970/month (7 hours/week × RMB 65 × 4.33 weeks); care worker at full load generates ~RMB 10,140/month, labor cost ~79% of revenue; 15 full-load care workers generate ~RMB 152,000/month revenue per site with ~4.7% net margin; break-even at ~12 full-load care workers. Two warnings: ① RMB 65/hour is the national ceiling; in cities with RMB 45/hour, the same model's net margin turns negative (labor cost elasticity 0.7, estimated ~-5.8%)—the Shanghai model cannot be extrapolated nationwide; ② 79% labor share = variable-cost-dominated, so volume growth generates almost no operating leverage—margin improvement can only come from price adjustment (locked) or labor efficiency; improvement lies in chain-scale dilution of management costs.
Rehabilitation single hospital (Mingzhou Ganbei Rehabilitation Hospital, first-hand acquisition announcement data): 297 beds, reached monthly break-even 22 months after opening (71.6% utilization that month, net profit +RMB 25,100); cultivation-period cumulative loss ~RMB 23.62 million over 3 years; 2023 revenue RMB 27.22 million, gross margin 23.8%, per-bed-day fee RMB 1,179; steady state (80% utilization, RMB 1,131/bed-day) annual revenue ~RMB 97.75 million, net margin ~9.7% (earnings commitment basis), acquisition consideration implies ~11.9-year static payback. This 9.7% is the upper bound of the best in-system case: some of the 6 affiliated hospitals Sanxing Medical planned to acquire in 2024 were "not yet profitable in 2023" (deal terminated after SSE inquiry), suggesting a long tail in single-hospital ramp-up periods; under tiered step-downs in per-day-bed prices, a system steady-state midpoint of 5%–8% is a safer assumption.
Aggregate mismatch: 7.679 million beds vs. 45.4% occupancy; locational mismatch: in Shanghai, over 2/3 of beds are in suburbs while over 3/4 of elderly live in urban areas; payment mismatch: nursing-type beds at 67.5% but institutional penetration only 5.1%—the bottleneck is public payment coverage (beneficiaries only 4.3% of disabled elderly), not beds; volume-price gap: 5.5 million care worker gap vs. 12,000 LTC insurance-designated institutions/~370,000 service personnel (1 service worker per ~5.2 beneficiaries).
Ranking of payment expansion's elasticity on unit economics: ① Rehab equipment and chains (higher elasticity)—+113,000 beds of capacity drives equipment procurement, and nationwide per-day-bed payment shortens single-hospital ramp-up; profit elasticity comes from operating leverage as utilization rises 53%→80%, but tiered price step-downs lock out price hikes; ② Home nursing stations (elastic within higher-tier cities, collapse risk on extrapolation)—volume converts directly to revenue, asset-light with no depreciation, but limited to high-price, high-density cities like Shanghai; ③ Inclusive institutions (lowest elasticity)—monthly fees locked by tiered pricing and payment capacity alike; LTC insurance institutional care benefits improve cash flow, not full-cost profitability. "Volume growth converts to profit" = rehabilitation (ramp-up phase) and higher-tier home care; "volume growth with locked prices does not convert to profit" = inclusive institutions and in-catalog services.
(Second headline section of this report: structure determines returns.)
Extremely fragmented: Institutional care CR3 is below 2% (the largest single player, Taikang Home, has ~23,000 residents, about 1% of the total residents in registered institutions nationwide); 91.5% of registered institutions have fewer than 300 beds; on the home-care side, there are 12,000 designated LTCI providers nationwide (March 2026), with the leader Fushoukang's 302 care stations accounting for about 2.5%; on the rehabilitation side, there are 628 private rehabilitation specialty hospitals (2021), with the Mingzhou group's 32 rehabilitation hospitals / over 10,000 beds accounting for about 5%. Landscape characteristics: regional fragmentation + slow rise of chain consolidation (Shanghai has cultivated 27 LTC care chain brands), with insurance capital becoming the main investor in high-end institutions.
① LTCI/medical insurance designated-provider qualifications and the ability to align with the national 36-item catalog (administrative barriers); ② long-duration capital—heavy-asset single projects take 6-8 years to reach breakeven, so only insurance capital can afford to play; ③ brand trust in elderly care services accumulates extremely slowly (lessons from prepaid-model collapses); ④ caregiver recruitment/training and standardized replication of the single-site model. Land/property (allocated land or negotiated transfer to cut costs) and synergy with insurance capital on the liability side (policies + residency eligibility locking in high-net-worth clients) are the most solid barriers on the institutional side.
Current state—profits are significantly skewed toward devices and the C-end, while the service side is squeezed thin by payment pricing: rehabilitation/home medical device gross margins are 63%-67% (Vishee net margin 29.8%, Yuwell net margin 18.6%); steady-state rehabilitation chains 5%-9.7%; home care stations about 4.7% (Shanghai); inclusive institutions are barely profitable or loss-making, and enterprise-type elder care institutions have negative operating profit (Taikang Foundation report). Listed device samples (Xiangyu + Vishee + Pumen) had combined 2025 revenue of about RMB 2.27 billion and net profit of about RMB 0.40 billion.
Migration direction (2026-2030): the payment pool expands from "a cumulative ~RMB 100 billion over 10 years" to "hundreds of billions of RMB per year," injecting systematic cash-flow certainty into the service side for the first time—but with volume growth and price locks, the margin ceiling of the service segment is capped by administrative pricing. The profit migration path: personal-pay high-end → fund-paid home care/rehabilitation → assistive devices (the NHSA has named "assistive device R&D, production and leasing" as a new growth point and is exploring payment coverage) → insurance capital on the financial side ("policy + service" converting thin operating margins into policy sales premiums). Pure elder care institution operations will remain a profit-relinquishing segment in the value chain over the long term.
Bargaining power upstream/downstream: weak versus payers (government funds)—government pricing + fee-for-service reimbursement, with 12,000 designated institutions competing for access; relatively strong versus personal-pay high-end clients (insurance capital locks in clients); weak versus caregiver supply—a gap of 5.5 million+ with rigid wage increases, and costs cannot be passed on under regulated prices; moderately weak versus property owners (urban-core renovation faces rigid rents; insurers with self-owned properties are not subject to this constraint).
| Player | Segment | Scale/Positioning | Profit/Valuation Anchor | One-Line Take |
|---|---|---|---|---|
| Taikang Home | Institutions · High-end CCRC | 48 projects in 37 cities, 32 in operation, ~23,000 residents, ~60,000 units planned | Breakeven per community 6-8 years, profitability in 8-10 years (group basis) | The only one to have made the "insurance + heavy-asset" national replication model work; moat lies in insurance capital and clients, not operations per se |
| Dajia Home | Institutions · Urban-core elder care | 16 urban-core communities in 14 cities (2025H1) | Not disclosed | Urban-core existing property conversion, lower capex than new-build CCRC; brand unproven |
| China Life system | Institutions + Investment | 20 projects in 16 cities, 7,700+ beds built/under construction; Grand Pension Fund invests in Fushoukang | Not disclosed | Ecosystem play: self-build + capital penetration of home care |
| Jiurucheng | Institutions · Private chain | Yangtze Delta regional leader; four-tier institution-community-home system | Not disclosed | Representative private light operator; direct beneficiary of LTCI volume growth but weaker capital than insurers |
| Fushoukang | Home care chain | 60+ cities, 302 care stations, ~20 million service visits/year (industry basis) | Unlisted; revenue mainly from LTCI payments | Closest to the "shovel seller" in home care, highest volume-growth certainty, but single-site net margin ~4.7% with high extrapolation-collapse risk |
| Sanshi Medical (601567) | Rehabilitation chains + Power distribution | Mingzhou group's 32 rehabilitation hospitals, 10,000+ beds; FY2025 revenue RMB 14.361 billion, net profit attributable RMB 1.274 billion (-43.6%, dragged by distribution) | PE(TTM) 36.75 / PB 1.37 (2026-11-15) | The purest rehabilitation chain positioning in A-shares; requires a split view: related-party acquisitions were once questioned, the company has been renamed "Sanshi Electric" and filed for HK listing, and the rehabilitation narrative is weakening |
| Vishee Medical (688580) | Rehabilitation devices | FY2025 revenue RMB 463 million (+15.7%), gross margin 66.2% | Net margin 29.8%; 2026Q3 revenue growth flat (−0.18%) | Highest earnings quality in devices, but in-hospital orders are a beta on hospital capex |
| Yuwell Medical (002223) | C-end home devices | FY2025 revenue RMB 7.955 billion (+5.1%), net profit RMB 1.482 billion | ROE 11.5%; PE(TTM) 23.85 / PB 2.12 (5th percentile of 10 years) | The most certain "real money" in the silver-hair C-end: self-pay pricing + brand repurchase + low valuation |
| Kelai Co. (301009) | Elderly consumption · Incontinence products | 2026 first three quarters revenue RMB 906 million (+9.2%) | Net profit −RMB 13 million, turning to loss; gross margin 22.8% | Right track, bad business: low margins + price war; sector boom not converting into profit |
SWS Medical Services (801156.SI; no dedicated SWS index for rehabilitation/elder care, so the closest proxy is used): PE 26.7x / 6th percentile since 2014, PB 3.58x / 19th percentile; SWS Medical Devices: PE 32.4x / 32nd percentile, PB 2.39x / 2nd percentile (2026-11-13 close). Interpret with caution: low percentile ≠ margin of safety—sector earnings are in a downward revision channel (Pumen 2025 net profit −46.7%, Vishee 2026Q3 revenue growth flat); if downward revisions spread, the effective valuation implied by static low percentiles will rise passively. But the PB 2% percentile also shows the market has already fully priced in pessimism about "services/devices not making money." With low valuation + expected payment volume expansion + ongoing earnings downgrades all overlapping, the conclusion is not "cheap, due for a rebound," but "you must pick the segment where earnings can be delivered."
Overall policy direction: positive, with the focus on the payment side. Timeline:
| Scenario | Probability | Narrative | Key Figures |
|---|---|---|---|
| Bear | 0.30 | Subsidy lapse/cut to RMB 5 billion, benefit approval stuck at 0.3%-0.5%, per-diem rates declining 3%-5% annually, hospital capex freeze continues | 2030: ~3.2 million beneficiaries / fund spending ~RMB 30.9 billion; public payment share ~26%; second wave of device-side profit cuts |
| Base | 0.50 | 2028 full (participation) coverage on time, subsidies normalized to ~RMB 20 billion, volume growth with flat prices | 2030: ~4 million beneficiaries / spending ~RMB 38.7 billion; public payment share ~31%; home-care upper-line net margin 5%-8%, rehabilitation steady-state 5%-8% |
| Bull | 0.20 | Beneficiaries exceed 4.8 million, subsidies institutionalized ≥RMB 30 billion, resident reimbursement ratios rise, caregiver professionalization subsidies in place | 2030 fund spending ≥RMB 46.4 billion; public payment share ~36%; home-care leaders' single-site net margin 10%+, device orders recovering 15%+ |
Exposing the value trap logic: bullish momentum ≠ worth buying. The three points in the bottom-right are this industry's most typical "huge demand but no profit" combination: inclusive institution operations (volume growth locked by both tiered pricing and payment capacity; 60% occupancy only breaks even on cash flow), Kelai Co. (aging penetration rising but price wars eat profits; revenue growth turning to loss), Fushoukang (highest home-care volume-growth certainty, but 79% labor share + unit-price extrapolation-collapse risk make profit conversion questionable—if the 2027 subsidy continuation lands and new-city unit prices are ≥RMB 55/hour, that position would migrate to the upper right). Core allocation is concentrated in the upper right: C-end home devices (self-pay pricing + brand repurchase) and high-end CCRC (market pricing + insurance capital synergy); Vishee/Sanshi sit near the midline—their momentum is real, but profits are respectively suppressed by the hospital capex cycle and per-diem price deflation.
Beneficiaries (base scenario):
Avoid:
(For individual stocks of interest—e.g., Sanshi Medical's healthcare segment split, Yuwell's category mix—separate dossiers can be created for single-stock research and target price work.)
| Scenario | Biggest Winners | Biggest Losers |
|---|---|---|
| Bear (0.30) | Yuwell Medical (C-end self-pay + low-percentile valuation), Taikang Home (high-net-worth self-pay, decoupled from public payments) | Vishee Medical (capex freeze), Sanshi Medical (per-diem deflation + long ramp-up tail), Fushoukang (extrapolation collapse) |
| Base (0.50) | Yuwell Medical, Taikang Home, Vishee Medical (structure hedges part of the cycle) | Kelai Co., inclusive institution operations |
| Bull (0.20) | Fushoukang/Yijia (single-site net margin above 10%), Sanshi Medical (volume growth covers price declines), Vishee Medical (orders recover) | No significant losers (sector-wide gains; laggards are pure self-pay high-end in relative terms) |
① LTCI financing sustainability: resident-segment fiscal dependence + spending-control orientation; benefit assessment tightening or benefit standard convergence shrinking; ② disability consumption subsidy lapse in 2027 (program expires at year-end); ③ with a 5.5 million caregiver gap, payment volume expansion becomes wage inflation rather than service supply; ④ per-diem payment tiered-decline deflation suppressing rehabilitation chain profitability; ⑤ hospital capex freeze continuing, second wave of device-side earnings downgrades; ⑥ low-percentile valuation trap: earnings downgrades raise effective valuations; ⑦ high-end CCRC exposed to wealth effects and interest rate environment (insurance capital duration mismatch risk).